Novel cytosine monophosphate medicine precursor

A cytarabine and drug technology, applied in the field of cytarabine monophosphate cyclic diester, can solve the problems of poor efficacy of hepatitis and liver cancer, etc.

Active Publication Date: 2005-12-21
美达贝斯制药有限公司
View PDF2 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Current therapies remain poorly effective against hepatitis and HCC due to dose limiting extrahepatic side effects or inadequate release of chemotherapeutic agents to target tissues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel cytosine monophosphate medicine precursor
  • Novel cytosine monophosphate medicine precursor
  • Novel cytosine monophosphate medicine precursor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0239] The synthesis of embodiment 1.3-oxo-3-(pyridine-4-yl)-pyruvate methyl ester (1)

[0240]

[0241] A 50 L three necked round bottom flask was equipped with an upper stirrer, heating pack and nitrogen inlet. A bottle was charged with THF (8 L) and potassium tert-butoxide (5 kg, 44.6 mol), then additional THF (18 L) was added. 4-acetylpyridine (2.5 kg, 20.6 mol) was added as the temperature increased, followed by dimethyl carbonate (3.75 L, 44.5 mol). After both ingredients were added, the temperature of the mixture was above 40°C. The reaction mixture was stirred without heating for 2.5 hours, during which time the temperature increased to an average temperature of about 55°C. The mixture was then heated to 57°C-60°C for 3 hours. The progress of the reaction was monitored by thin layer chromatography (TLC). The heat was turned off and the mixture was allowed to cool slowly overnight (15 hours). The mixture was then filtered through a 45 cm Buchner funnel. The pot...

Embodiment 2

[0244] Example 2. Synthesis of (S)-3-hydroxyl-3-(pyridine-4-yl)-acetone methyl ester (2)

[0245]

[0246] A 22 L three necked round bottom flask was fitted with upper stirrer, thermowell / thermometer, addition funnel (1 L) and cooler (empty). The flask was purged with nitrogen, charged with formic acid (877 g) and cooled with an ice bath. Triethylamine (TEA) (755 g) was charged to the addition funnel and slowly added to the stirred formic acid at intervals over 50 min. There was an exothermic reaction with moderate fuming which disappeared as the addition approached the end. When the addition was complete, the cooling bath was removed and the reaction product was diluted with dimethylformamide (DMF) (0.5 L). Ketoester 1 (2648 g) was added in one portion, followed by an additional 0.5 L of DMF in an endothermic reaction. The temperature will drop by about 5°C, which indicates that ketoester 1 is insoluble. The flask was fitted with a heating pack, and the stirred mixture...

Embodiment 3

[0252] Example 3. Synthesis of (S)(-)-1-(4-pyridine)-1,3-propanediol

[0253]

[0254]A 22 L four necked round bottom flask was fitted with upper stirrer, thermometer well / thermometer, addition funnel (2 L), condenser and cooler (empty). The flask was purged with nitrogen and charged sequentially with sodium borohydride (419 g) and 1-butanol (9.0 l). The crude hydroxyester (2) was dissolved in 1-butanol (1.0 L, the total volume of the solution was 3.2 L). A quarter (800 mL) of the hydroxyester solution was slowly added to the stirred sodium borohydride slurry at intervals over 90 minutes. The temperature increased from 19°C to 32°C and moderate gas evolution occurred. The mixture was stirred for 45 minutes, reaching a maximum temperature of 36°C. A second quarter of the hydroxyester solution was added slowly at intervals over 45 minutes, increasing the temperature from 36°C to 52°C. The mixture was stirred for 20 minutes while the maximum temperature reached 57°C. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

The invention discloses a compound of chemical formula I and its preparation method and application. In the compound of chemical formula I: M and V are mutually cis, and MH is cytarabine; the 5' oxygen of the above cytarabine Linked to phosphorus; V is 4-pyridyl; and pharmaceutically acceptable drug precursors and salts thereof.

Description

[0001] This application claims priority to US Provisional Application No. 60 / 423,259, filed October 31, 2002, and US Provisional Application No. 60 / 423,211, filed October 31, 2002, the entire contents of which are hereby incorporated by reference. technical field [0002] The present invention relates to novel cyclic diesters of cytarabine monophosphate (araCMP) of 1,3 propane-1-aryl diols, their preparation and use. More specifically, the present invention relates to the field of cyclic diesters of cytarabine monophosphate (araCMP) of 1,3 propane-1-(4-pyridyl)diol having the cis stereochemical configuration. Background technique [0003] The following description of the background art of the present invention is provided to help the understanding of the present invention, but does not constitute or describe the prior art of the present invention. The entire contents of all publications are incorporated herein by reference. [0004] AraC is an analog of deoxycytidine that i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07H19/10
Inventor 塞尔日·H·布瓦耶马克·D·埃里恩
Owner 美达贝斯制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products